{"id":2051,"date":"2020-04-15T14:42:00","date_gmt":"2020-04-15T13:42:00","guid":{"rendered":"https:\/\/www.corsiaffariregolatori.it\/it\/?p=2051"},"modified":"2022-01-17T14:43:44","modified_gmt":"2022-01-17T13:43:44","slug":"drug-shortage-covid-19","status":"publish","type":"post","link":"https:\/\/www.direnzo.biz\/it\/drug-shortage-covid-19\/","title":{"rendered":"Drug shortage, EMA actions to contain pandemic crisis"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The emergency situation generated by the&nbsp;<a href=\"https:\/\/www.who.int\/news-room\/q-a-detail\/q-a-coronaviruses\" target=\"_blank\" rel=\"noreferrer noopener\">spreading of the COVID-19<\/a>&nbsp;contagion is having a relevant impact on health systems, not only in the workload of doctors and hospitals, but also in the&nbsp;<strong>availability of drugs<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">According to the&nbsp;<a href=\"https:\/\/www.ema.europa.eu\/en\" target=\"_blank\" rel=\"noreferrer noopener\">European Medicines Agency<\/a>, in fact, many Member States of the European Union are reporting a reduction of the&nbsp;<strong>stocks<\/strong>&nbsp;<strong>of<\/strong>&nbsp;those&nbsp;<strong>medicines<\/strong>&nbsp;used for the treatment of coronavirus patients:&nbsp;<strong>shortages<\/strong>&nbsp;are therefore to be expected soon for these medicines.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Some of these medicines are well-known: tocilizumab, currently under clinical trial, but already authorised for the treatment of rheumatoid arthritis; hydroxychloroquine, used in less severe patients, as well as some antivirals, generally used to treat HIV.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These drugs risk&nbsp;<strong>shortages<\/strong>&nbsp;as they are usually manufactured for a minor and different demand. Now, however, a massive, compassionate or off-label use \u2013 at national level \u2013 adds to a routine use according to the indications.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The situation is similar for some other drugs, used as indicated, but in higher quantities than usual, such as the medicines used in intensive care units (e.g. anaesthetics or muscle relaxants).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">EMA and all national agencies (including the Italian Medicine Agency AIFA) expected and monitored the development of the situation since the pandemic outbreak, putting in place a series of measures to prevent&nbsp;<a href=\"https:\/\/www.direnzo.biz\/it\/?p=2329\"><strong>drug shortages<\/strong><\/a>, although mainly focusing at the beginning on manufacturing issues following the block of all activities, especially in China.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Carefully assessing all causes at the root of the shortages (isolated factories, closed borders, etc.) EMA has decided to intervene, implementing a series of measures aiming at mitigating as much as possible the impact of the pandemic on the&nbsp;<strong>supply chain of medicines<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In particular, thanks to an executive group dedicated to&nbsp;<strong>shortages of medicines<\/strong>&nbsp;caused by major events, EMA is setting up, in cooperation with the pharmaceutical industry, the so called \u2018<a href=\"https:\/\/www.assogenerici.it\/it\/notizie\/2927-ema-in-campo-contro-le-carenze-di-medicinali-rete-i-spoc-per-le-aziende.html\"><em>i-SPOC<\/em><\/a>\u2019, the industry single point of contact system, allowing each pharmaceutical company to report any shortage directly to EMA. The system provides for the appointment of an i-SPOC inside every pharmaceutical company, with the task of transmitting to the Agency information on any current or expected shortage of medicines related to COVID-19.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">National agencies will still be competent in their own territory, but given the exceptional circumstances, the European Agencies will take on a central role in coordinating any action to be taken. It is also possible that the Agency sets up new and more specific procedures to&nbsp;<strong>manage shortages<\/strong>, reserving the use of new resources to their solution.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For the moment, EMA is collecting information \u2013 as much detailed as possible \u2013 on drug shortages at national level, but other, more concrete, measures are on their way. In fact, the Agency intends to increase the production capacity of the single States: to this purpose, they are working to speed up the approval of new manufacturing lines or sites in the EU, with special reference to medicines risking shortage.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Agency is also discussing the possibility to \u2018loose\u2019 some norms and make them more flexible, to ensure the supply of essential drugs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">While waiting for the Q&amp;As document, currently under preparation, EMA undertook all actions required to guarantee the right to health for all European citizens, not last the evaluation of the active substances export ban decided by India, that triggered the prompt reaction of the American President Donald Trump.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Written by: Maria Pia Felici<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The emergency situation generated by the&nbsp;spreading of the COVID-19&nbsp;contagion is having a relevant impact on health systems, not only in the workload of doctors and hospitals, but also in the&nbsp;availability of drugs. According to the&nbsp;European Medicines Agency, in fact, many Member States of the European Union are reporting a reduction of the&nbsp;stocks&nbsp;of&nbsp;those&nbsp;medicines&nbsp;used for the treatment<br \/><a class=\"moretag\" href=\"https:\/\/www.direnzo.biz\/it\/drug-shortage-covid-19\/\">+ Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":2049,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[],"class_list":["post-2051","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/posts\/2051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/comments?post=2051"}],"version-history":[{"count":0,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/posts\/2051\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/media\/2049"}],"wp:attachment":[{"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/media?parent=2051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/categories?post=2051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.direnzo.biz\/it\/wp-json\/wp\/v2\/tags?post=2051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}